NET PROFIT (x1000 DKK)
NeoProteomics AB
Closing information (x1000 DKK)
| Closing information | 2022/12 | 2021/12 | 2020/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
32
|
35
|
35 |
| Earnings before taxes |
-76
|
-48
|
-191 |
| EBITDA |
-44
|
-14
|
-157 |
| Total assets |
3,862
|
4,132
|
4,225 |
| Current assets |
75
|
18
|
33 |
| Current liabilities |
2,972
|
3,135
|
3,161 |
| Equity capital |
890
|
996
|
1,064 |
| - share capital |
74
|
80
|
82 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2022/12 | 2021/12 | 2020/12 |
| Solvency |
23.0%
|
24.1%
|
25.2% |
| Turnover per employee | |||
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-1.1%
|
-0.3%
|
-3.7% |
| Current ratio |
2.5%
|
0.6%
|
1.0% |
| Return on equity (ROE) |
-8.5%
|
-4.8%
|
-18.0% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
0
|
-2 |
| Chg. No. of employees % | -100% |
Total value of public sale
| Fiscal year | 2022/12 | 2021/12 | 2020/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.